Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4
DOC Updates19 Touko

Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition.

This special episode is sponsored with support from Corcept.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John Buse, MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award

Selected references:

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care April 2025

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025

MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live March 2026

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(100)

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates ...

17 Elo 33min

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Elo 35min

Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!

Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!

Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease...

10 Elo 32min

Special Edition: Hypertension Part I—Overview and Management

Special Edition: Hypertension Part I—Overview and Management

In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure....

6 Elo 33min

Special Edition: Highlights from the ADA's 2026 Scientific Sessions

Special Edition: Highlights from the ADA's 2026 Scientific Sessions

In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On ...

30 Heinä 44min

Special Edition: Lp(a) & CV Risk

Special Edition: Lp(a) & CV Risk

Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing unders...

24 Heinä 34min

Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations

Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations

Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therap...

17 Heinä 25min

Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available ...

7 Heinä 28min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-pitaisko-erota
psykopodiaa-podcast
meditaatiot-suomeksi
voi-hyvin-meditaatiot-2
terapiassa
rss-uplevel-by-sonja-hannus
selviytyjat-tarinoita-elamasta
paritellen
junnut-pelissa
rss-seksicast
rss-pt-paahtio
rss-mighty-finland-podcast
rss-vapaudu-voimaasi
rss-kuumilla-aalloilla
yes-girl
kehorauhaa
ruokaklinikka